Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Emerging evidence challenges it
This serves as a call for more proactive research efforts on the topic of GLP-1 RA use in patients undergoing concurrent EGD and colonoscopy in order to help develop guidelines and cautious risk mitigation policies for the peri-procedural management of this patient population
More recently, tirzepatide a synthetic 39-amino-acid peptide that dual-agonizes GLP-1 and GIP receptors was approved as Mounjaro (diabetes, 2022) and Zepbound (obesity, 2023)
Prioritize protein and resistance training This does not reduce GI side effects but it directly counters the muscle loss risk, which is the most consequential long-term side effect for body composition
Reduces hyperpigmentation
